Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Real-World efficiency of Pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment

We are pleased to inform you that another EMR real-world study “Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment” has been published in EJC Skin Cancer. This study examines the effectiveness of retreating stage III melanoma patients with pembrolizumab, an anti-PD1 antibody, following the failure of initial adjuvant immunotherapy. Using data from our Registry, we analysed 74 patients, focusing on response rates and progression-free survival (PFS) based on recurrence timing and reasons for discontinuing the initial treatment. The overall response rate (ORR) to pembrolizumab retreatment was 37.3%, with no significant difference between early (40.9%) and late recurrences (34.5%). Notably, patients who stopped initial treatment due to side effects showed a higher response rate (52.9%) than those who completed treatment (37.5%) or discontinued due to disease progression (23.1%). PFS was similar across groups, with median PFS at 7.4 months for early recurrence and 6.1 months for late recurrence. The findings suggest pembrolizumab retreatment is particularly promising for patients who discontinued prior immunotherapy due to toxicity.